119 related articles for article (PubMed ID: 24288736)
1. Study of antitumor activity of antibodies to TNF-α on Walker carcinosarcoma model.
Yurlova EI; Krylova SG; Dugina JL; Epstein OI
Bull Exp Biol Med; 2013 Sep; 155(5):673-5. PubMed ID: 24288736
[TBL] [Abstract][Full Text] [Related]
2. [INFLUENCE OF ANGIOPROTECTOR DRUGS ON THE EFFICACY OF CYTOSTATIC THERAPY (EXPERIMENTAL STUDY)].
Trashkov AP; Vasil'ev AG; Kovalenko AL; Petrov AY; Valeev VV
Eksp Klin Farmakol; 2016; 79(2):34-9. PubMed ID: 27416681
[TBL] [Abstract][Full Text] [Related]
3. Proliferation of Walker 256 carcinosarcoma cells: effect of whole-body hyperthermia and antitumor agents.
Lushnikova EL; Ovsyanko EV; Nepomnyashchikh LM; Efremov AV; Morozov DV
Bull Exp Biol Med; 2011 Nov; 152(1):146-52. PubMed ID: 22803062
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats.
Alves de Souza CE; Alves de Souza HM; Stipp MC; Corso CR; Galindo CM; Cardoso CR; Dittrich RL; de Souza Ramos EA; Klassen G; Carlos RM; Correia Cadena SMS; Acco A
Free Radic Biol Med; 2017 Sep; 110():228-239. PubMed ID: 28629835
[TBL] [Abstract][Full Text] [Related]
5. Sesquiterpene lactones of Moquiniastrum polymorphum subsp. floccosum have antineoplastic effects in Walker-256 tumor-bearing rats.
Martins GG; Lívero FA; Stolf AM; Kopruszinski CM; Cardoso CC; Beltrame OC; Queiroz-Telles JE; Strapasson RL; Stefanello MÉ; Oude-Elferink R; Acco A
Chem Biol Interact; 2015 Feb; 228():46-56. PubMed ID: 25616030
[TBL] [Abstract][Full Text] [Related]
6. [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats].
Plotnikov MB; Maslov MIu; Aliev OI; Vasil'ev AS; Zueva EP; Krylova SG; Shilova NV
Vopr Onkol; 2001; 47(3):335-7. PubMed ID: 11544834
[TBL] [Abstract][Full Text] [Related]
7. Energy controllable steep pulse (ECSP) treatment suppresses tumor growth in rats implanted with Walker 256 carcinosarcoma cells through apoptosis and an antitumor immune response.
Luo XD; Sun JC; Liu F; Hu LN; Dong XJ; Sun DN; Xiao J
Oncol Res; 2012; 20(1):31-7. PubMed ID: 23035363
[TBL] [Abstract][Full Text] [Related]
8. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma.
Camargo CA; Gomes-Marcondes MC; Wutzki NC; Aoyama H
Anticancer Res; 2012 Jan; 32(1):129-33. PubMed ID: 22213297
[TBL] [Abstract][Full Text] [Related]
9. [Enhancement of Walker-256 antitumor effect by intra-arterial administration of TNF before using mitomycin C].
Sato T; Sekine S; Katsumi S
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2392-5. PubMed ID: 3137875
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a polychlorinated biphenyl mixture, Aroclor 1254, in rats inoculated with Walker 256 carcinosarcoma cells.
Kerkvliet NI; Kimeldorf DJ
J Natl Cancer Inst; 1977 Sep; 59(3):951-5. PubMed ID: 408506
[No Abstract] [Full Text] [Related]
11. [The effect of ferromagnet particles on the growth of Walker carcinosarcoma 256 in Wistar rats].
Volkonskiĭ VA
Eksp Onkol; 1990; 12(2):74-6. PubMed ID: 2318139
[TBL] [Abstract][Full Text] [Related]
12. Aprotinin and growth of Walker 256 carcinosarcoma in the rat.
Thomson AW; Pugh-Humphreys RG; Horne CH; Tweedle DJ
Br J Cancer; 1977 Apr; 35(4):454-60. PubMed ID: 300627
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat.
Kooistra KL; Rodriguez M; Powis G
Cancer Res; 1989 Feb; 49(4):977-82. PubMed ID: 2912564
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations.
Pigatto MC; Roman RM; Carrara L; Buffon A; Magni P; Dalla Costa T
Eur J Pharm Sci; 2017 Jan; 97():70-78. PubMed ID: 27816627
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs.
Ovsjanko EV; Lushnikova EL; Larionov PM; Arkhipov SA; Nepomnyashchikh LM; Efremov AV; Ovsjanko YU
Bull Exp Biol Med; 2009 Oct; 148(4):650-5. PubMed ID: 20396763
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor (VEGF-A) in rat mandibular salivary gland during paraneoplastic process and treatment with cyclophosphamide and melatonin.
Ovsyanko EV; Kulishenko AO; Lushnikova EL; Vinogradov AS; Zhurakovskii IP; Pustovetova MG; Ovsyanko YU
Bull Exp Biol Med; 2015 Mar; 158(5):676-80. PubMed ID: 25778658
[TBL] [Abstract][Full Text] [Related]
17. Effect of N-acetylcysteine on the antitumor activity of cyclophosphamide against Walker-256 carcinosarcoma in rats.
Harrison EF; Fuquay ME; Hunter HL
Semin Oncol; 1983 Mar; 10(1 Suppl 1):25-8. PubMed ID: 6836324
[No Abstract] [Full Text] [Related]
18. Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in walker 256 carcinosarcoma in rats.
Gold J
Oncology; 1975; 31(1):44-53. PubMed ID: 51492
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of growth and sensitivity to cytostatics of Walker 256 carcinosarcoma in randombred and Wistar rats].
Karaivanova MK
Eksp Med Morfol; 1974; 13(4):237-42. PubMed ID: 4219353
[No Abstract] [Full Text] [Related]
20. Potentiation by clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma.
Gold J
Cancer Biochem Biophys; 1978; 3(1):41-5. PubMed ID: 552898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
